Abstract BACKGROUND: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. PATIENTS AND METHODS: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CML WP over a 40-year period. RESULTS: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old) particularly for the frequency of splenomegaly (71%, 63% and 55%, P < 0.001), and the greater spleen size (median value: 4.5, 3.0 and 1.0 cm, P < 0.001). According to the EUTOS score, that is age-independent, high-risk patients were more frequent among YAs, than among adult and elderly patients (18%, 9% and 6%, P < 0.001). In tyrosine kinase inhibitors-treated patients, the rates of complete cytogenetic and major molecular response were lower in YAs, and the probability of transformation was higher (16%, 5% and 7%, P = 0.011). CONCLUSIONS: The characteristics of CML or the host response to leukemia differ with age. The knowledge of these differences and of their causes may help to refine the treatment and to improve the outcome. CLINICAL TRIAL NUMBERS: NCT00510926, NCT00514488, NCT00769327, NCT00481052.

Differences among young adults, adults and elderly chronic myeloid leukemia patients.

SAGLIO, Giuseppe;FAVA, Carmen;Boccadoro, M;FERRERO, Dario;
2015-01-01

Abstract

Abstract BACKGROUND: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. PATIENTS AND METHODS: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CML WP over a 40-year period. RESULTS: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old) particularly for the frequency of splenomegaly (71%, 63% and 55%, P < 0.001), and the greater spleen size (median value: 4.5, 3.0 and 1.0 cm, P < 0.001). According to the EUTOS score, that is age-independent, high-risk patients were more frequent among YAs, than among adult and elderly patients (18%, 9% and 6%, P < 0.001). In tyrosine kinase inhibitors-treated patients, the rates of complete cytogenetic and major molecular response were lower in YAs, and the probability of transformation was higher (16%, 5% and 7%, P = 0.011). CONCLUSIONS: The characteristics of CML or the host response to leukemia differ with age. The knowledge of these differences and of their causes may help to refine the treatment and to improve the outcome. CLINICAL TRIAL NUMBERS: NCT00510926, NCT00514488, NCT00769327, NCT00481052.
2015
26
1
185
192
Castagnetti, F; Gugliotta, G; Baccarani, M; Breccia, M; Specchia, G; Levato, L; Abruzzese, E; Rossi, G; Iurlo, A; Martino, B; Pregno, P; Stagno, F; Cuneo, A; Bonifacio, M; Gobbi, M; Russo, D; Gozzini, A; Tiribelli, M; de Vivo, A; Alimena, G; Cavo, M; Martinelli, G; Pane, F; Saglio, G; Rosti, G; Gimema, CML Working Party including Salvi F; Pini, M; Leoni, P; Rupoli, S; Galieni, P; Bigazzi, C; Cantore, N; Palmieri, F; Albano, F; Russo Rossi, A; Rambaldi, A; Intermesoli, T; Palandri, F; Testoni, N; Luatti, S; Soverini, S; Iacobucci, I; Bochicchio, Mt; Apolinari, M; Fogli, M; Cervello, I; Capucci, A; Malagola, M; Malpignano, A; Girasoli, M; Angelucci, E; Usala, E; Storti, S; De Biasi, E; Tagariello, G; Sartori, R; Di Raimondo, F; Vigneri, P; Impera, S; Molica, S; Lanza, F; Viganò, C; Grasso, M; Rapezzi, D; Cavazzini, F; Bosi, A; Santini, V; Capalbo, Sf; Spinosa, G; Pierri, I; Bergamaschi, M; Carella, Am; Bacigalupo, A; De Blasio, A; Ciccone, F; Di Renzo, N; Musolino, C; Russo, S; Cortelezzi, A; Morra, E; Pungolino, Em; Luppi, M; Marasca, R; Pogliani, Em; Gambacorti-Passerini, C; Luciano, L; Ferrara, F; Annunziata, M; Latte, G; Noli, D; Rege-Cambrin, G; Fava, C; Semenzato, G; Binotto, G; Fabbiano, F; Turri, D; Siragusa, S; Caracciolo, C; Musso, M; Porretto, F; Aversa, F; Crugnola, M; Cazzola, M; Orlandi, E; Falini, B; Falzetti, F; Visani, G; Isidori, A; Fioritoni, G; Di Lorenzo, R; Vallisa, D; Trabacchi, E; Petrini, M; Galimberti, S; Pizzuti, M; Zaccaria, A; Salvucci, M; Ronco, F; Ielo, D; Merli, F; Avanzini, P; Tosi, P; Merli, A; Musto, P; De Stefano, V; Sica, S; Latagliata, R; De Fabritiis, P; Trawiska, M; Majolino, I; Pacilli, L; Ronci, B; Cedrone, M; Petti, Mc; Pisani, F; Tafuri, A; Montefusco, E; Iuliano, F; Dore, F; Pardini, S; Bocchia, M; Defina, M; Liberati, Am; Luzzi, D; Boccadoro, M; Ferrero, D; Vitolo, U; Gherlinzoni, F; Calistri, E; Fanin, R; Pizzolo, G; Meneghini, V; Rodighiero, F; D'Emilio, A
File in questo prodotto:
File Dimensione Formato  
Ann Oncol-2015-Castagnetti-185-92.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 213.35 kB
Formato Adobe PDF
213.35 kB Adobe PDF Visualizza/Apri
[PUBLISHED Vsn] Castagnetti et al - Ann Oncol-2015-Castagnetti-185-92.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 213.35 kB
Formato Adobe PDF
213.35 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/152598
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 71
  • ???jsp.display-item.citation.isi??? 62
social impact